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Abstract Neurogenic bladder sphincter dysfunction
(NBSD) can cause severe and irreversible renal damage
and bladder-wall destruction years before incontinence
becomes an issue. Therefore, the first step in adequate
management is to recognize early the bladder at risk for
upper- and lower-tract deterioration and to start adequate
medical treatment proactively. Clean intermittent catheter-
ization combined with anticholinergics (oral or intravesical)
is the standard therapy for NBSD. Early institution of such
treatment can prevent both renal damage and secondary
bladder-wall changes, thereby potentially improving long-
term outcomes. In children with severe side effects or with
insufficient suppression of detrusor overactivity despite
maximal dosage of oral oxybutynin, intravesical instillation
is an effective alternative. Intravesical instillation eliminates
systemic side effects by reducing the first-pass metabolism
and, compared with oral oxybutynin, intravesical oxybutynin
is a more potent and long-acting detrusor suppressor. There
is growing evidence that with early adequate treatment,
kidneys are saved and normal bladder growth can be
achieved in children so they will no longer need surgical





NBSD neurogenic bladder sphincter dysfunction
MMC myelomeningocele
CIC clean intermittent catheterization
CISC clean intermittent self-catheterization
DSD detrusor sphincter dyssynergia
Introduction
Neurogenic bladder sphincter dysfunction (NBSD) can
develop as a result of a lesion at any level in the nervous
system, including the cerebral cortex, spinal cord, or
peripheral nervous system. Neurologic conditions in chil-
dren leading to neurogenic bladder dysfunction are pre-
dominantly congenital neural tube defects (including
myelomeningocele, lipomeningocele, sacral agenesis, and
occult lesions causing tethered cord). Acquired causes such
as spinal cord tumors or trauma or sequelae of transverse
myelitis are less frequent. Whereas from an etiologic
standpoint neurogenic bladder dysfunction is a heteroge-
neous group, medical management will be similar irrespec-
tive of the underlying cause. The vast majority of
knowledge about NBSD management comes from long-
term experience with myelomeningocele (MMC), the most
common neural tube defect.
Following the institution of a general treatment policy
with advances in neurosurgical and orthopedic treat-
ments in previous decades, governing the associated
NBSD has become crucial for improving quality of life
and life expectancy in children with neural tube defects.
In MMC patients, disordered innervation of the detrusor
musculature and external sphincter adversely affects
bladder function, which if untreated not only leads to
Pediatr Nephrol (2008) 23:717–725
DOI 10.1007/s00467-007-0691-z
DO00691; No of Pages
C. Verpoorten (*): G. M. Buyse
Department of Child Neurology,
University Hospitals K.U. Leuven,
Herestraat 49,
B-3000 Leuven, Belgium
e-mail: carla.verpoorten@uzleuven.beincontinence but also will cause secondary damage and
dysfunction of both the upper and lower urinary tracts.
Key elements in optimal NBSD management are early
diagnosis (including NBSD typology) and early (pre-
symptomatic) institution of adequate medical treatment.
There is indeed growing evidence that management
decisions made during infancy, which prevent both renal
damage and secondary bladder-wall changes, potentially
impact long-term outcomes for renal function and safe
urinary continence.
After describing the pathophysiology of NBSD and its
possible consequences, this paper focuses on diagnosis
(including early identification of patients at risk), treat-
ment goals, treatment tools, and practical management of
NBSD.
Historical evolution
The management of NBSD in children has undergone
major changes over the years. A first milestone was the
introduction of clean intermittent catheterization (CIC) in
1972 [1]. CIC (combined with anticholinergics if required)
has made “conservative” (medical) management a suc-
cessful treatment option, with a good outcome for quality
of life and kidney protection. Further important break-
throughs were the wider application of urodynamic testing
in the evaluation of infants and young children with
suspected NBSD [2–4] and the better pathophysiological
understanding of the natural history of NBSD in patients
with spina bifida. In spina bifida, the natural history of the
urinary tract in untreated NBSD is one of progressive
d e t e r i o r a t i o nb yt h ea g eo f3y e a r si nu pt o5 8 %o fp a t i e n t s
[5]. Several reports have shown this deterioration to be
directly related to increased intravesical pressure. In 1981,
the bladder pressure at which urethral leakage occurred
was found to be a useful predictor of unsafe bladder
function [2]. The leak-point pressure, as it is now
commonly referred to, has become accepted as one of
the urodynamic parameters that allows clinicians to
differentiate patients with relatively low or high risk for
subsequent upper urinary tract deterioration. In 1984,
detrusor external sphincter dyssynergia (DSD) was iden-
tified as an important factor leading to functional obstruc-
tion, and intravesical pressure was recognized as the
pathophysiological mechanism of subsequent upper uri-
nary tract deterioration [3]. Shortlythereafter,urodynamics
in infants and children was shown to allow a functional
classification of NBSD that correlated with clinical entities
of incontinence and obstruction, an approach that has
allowed the concept of individualized and presymptomatic
therapy in high-risk patients [6].
Pathophysiology of the neurogenic bladder
Under normal conditions, the detrusor muscle, bladder neck,
and striated external sphincter function as a synergistic unit
for adequate storage and complete evacuation of urine. In
healthy bladders, the change in bladder-filling pressure
between empty and full is normally less than 10–15 cm
H2O. Normal voiding pressures for males and females are
from 50 to 80 cm H2O and from 40 to 65 cm H2O,
respectively [7].
In patients with NBSD, disordered innervation of the
detrusor musculature and external sphincter adversely
affects bladder function. In recent years, it has become
clear that children with this condition can be categorized
into high- and low-risk groups for secondary damage from
a neurogenic bladder based on intravesical pressure. When
the detrusor (filling) pressure exceeds 40 cm H2O,
glomerular filtration rate decreases and pyelocaliceal and
ureteral drainage deteriorates, leading to obstructive
hydronephrosis and/or vesicoureteral reflux [2, 8–10]. Even
in the absence of reflux or upper urinary tract dilatation,
high intravesical pressure can impair drainage of urine into
the bladder. Any pathophysiologic process that causes
either intermittent or continuous elevation of bladder
pressure above 40 cm H2O places the child at risk for
upper urinary tract dysfunction, urinary tract infections, and
ultimately renal failure. Intermittent elevation of bladder
pressure may occur from detrusor hypertonia, hyperreflexia,
or both. Hyperreflexia may cause intermittent elevation of
bladder pressure, especially if the external sphincter acts
reflexively and tightens rather than relaxes in an attempt to
prevent micturition [detrusor sphincter dyssynergia (DSD)].
Over a long period of time, hyperreflexia with pressures
greater than 40 cm H2O may result in detrusor decompen-
sation (areflexia from myogenic failure) or in detrusor
hypertrophy with associated sacculations and subsequent
diverticula formation. These pathophysiologic changes
affect the elastic and vesicoelastic properties of the bladder
and also result in mechanical ureterovesical junction
obstruction. Continuous elevation of bladder pressure
above 40 cm H2O may occur from a hypertonic detrusor
or a hypertrophic small-capacity bladder secondary to
outflow obstruction [11]. Bladder outlet obstruction is
caused by DSD, or by fibrosis of the external urethral
sphincter secondary to partial or complete denervation [3,
12, 13]. Bladder outlet obstruction will lead to elevated
(pathologic) voiding pressures, which will contribute to
either detrusor decompensation or hypertrophy. Finally,
recurrent urinary tract infections due to bladder residue may
aggravate damage to the neurogenic bladder through
processes of transmural inflammation and fibrosis. Together
with high intravesical pressures and/or vesicoureteral
reflux, these lower urinary tract infections will lead to
718 Pediatr Nephrol (2008) 23:717–725episodes of acute pyelonephritis and irreversible renal
damage.
Management of the neurogenic bladder
General principles and treatment goals
The cornerstone of optimal NBSD management is early
identification and characterization (typology) and the
institution of proactive therapy. Crucial for long-term
prognosis of patients with NBSD is the fact that the
management must start before consequences of bladder
dysfunction become apparent. From the outset, the goals of
management are to prevent or minimize secondary damage
to the upper urinary tracts and bladder from the primary
neurogenic bladder dysfunction and to achieve safe social
continence [14]. Thus, long before continence becomes an
issue, starting from the first year of life, management is
directed at creating a low-pressure reservoir and ensuring
complete and safe bladder emptying.
Clean intermittent catheterization (CIC) or self-
catheterization (CISC) in combination with anticholiner-
gics (oxybutynin) is the standard therapy for children
with neurogenic bladder dysfunction with detrusor hyper-
activity and/or DSD [11, 15, 16]. This treatment is also
feasible and effective in developing countries, where
untreated neuropathic bladder is an important cause of
preventable chronic renal failure [17, 18]. CIC enables
complete bladder emptying and thus avoids bladder
residues and consequent risks for infections. In the high-
risk bladder with DSD, CIC also allows bladder emptying
before the occurrence of otherwise “spontaneous” high-
pressure voiding, which is known to be detrimental for
kidney function and drainage. Oxybutynin, a bladder
smooth-muscle relaxant, is used to improve bladder
dynamics through suppression of detrusor hypertonicity
and hyperreflexia. By doing so, oxybutynin eliminates
(high-pressure) uninhibited detrusor contractions (and thus
urinary leakage) and prevents high-pressure bladder storage
(due to detrusor hypertonicity or low bladder compliance)
and high-pressure emptying (in case of DSD).
Early management, including diagnosis and identification
of the high-risk bladder
At birth, the majority of patients with neurogenic bladder
has normal upper urinary tracts. Without proper manage-
ment, urinary tract infections and elevated bladder pressures
with secondary bladder-wall changes may cause upper
urinary tract deterioration within 3 years in up to 58% [5].
One third of children who develop impaired kidney
drainage do so within the first year of life [19]. The
specific abnormalities vary considerably and are not
predicted by the level of the spinal cord defect. Further-
more, the dysfunctional pattern may be dynamic, influ-
enced by spinal cord surgery, tethering, and denervation. In
the initial baseline evaluation, clinical observations must be
completed with urinalysis (microscopy and culture), renal/
bladder ultrasound, and cystourethrogram. These allow the
experienced clinician to suspect the type of NBSD and to
identify the high-risk subgroup. The next consideration is
when to perform urodynamic studies.
Two different opinions exist in the literature on the use
of urodynamic studies in the early evaluation and further
follow-up. In one approach, urodynamic assessment has
become an integral part of the initial evaluation and
subsequent management, as it allows recognition of the
different subtypes of NBSD (typology), proactive interven-
tions, evaluation and guidance of therapy, and early
detection of neurologic deterioration (such as symptomatic
tethering of the spinal cord [20]). Advocates justify this
approach of routine urodynamics to minimize the deleteri-
ous effects of high intravesical pressure by directly
measuring it rather than indirectly suspecting it from the
development of upper and lower urinary tract changes on
serial radiologic imaging. Several studies have shown that
early urodynamic evaluation of children with NBSD allows
the prediction of which newborns are at risk for upper
urinary tract deterioration. Urodynamic risk factors are low
bladder compliance, intravesical pressure more than 40 cm
H2O, and DSD [2, 3, 6, 21]. The alternative to urodynamic-
based management is serial radiologic imaging to detect
secondary evidence of high bladder pressure. Critics of
newborn and early infancy urodynamics refer to a lack of
standards for performance and interpretation, which might
lead to unnecessary interventions [22, 23]. Those authors
recommend careful history, physical examination, upper
urinary tract imaging, and close follow-up during infancy
and childhood, reserving urodynamic studies only for
patients with evidence of urinary retention on physical
examination, new-onset hydronephrosis or febrile urinary
tract infection, or for evaluation to achieve continence.
Proponents of this approach with selective urodynamics
suggest that close monitoring with prompt intervention at
first signs of deterioration is effective in protecting the upper
urinary tracts (including preservation of nephrons and thus
renal function in the long run). A remaining concern,
however, could be that in this more expectant approach, high
intravesical pressures may have already resulted in irrevers-
ible and avoidable damage to the bladder wall, resulting in
small-capacity, low-compliance bladders later in life.
Although many questions regarding optimal evaluation
and management remain unanswered, the consensus on the
need of close surveillance, especially in the first years of
life, plus the possibility that proactive treatment may be
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need for an integrated approach in which clinical observa-
tions, serial imaging, and urodynamics are the basis for
early adequate treatment.
Urodynamic studies: special considerations in children
with NBSD
If properly performed, even with possible shortcomings in
newborns and infancy, urodynamic studies allow direct
diagnosis of NBSD and recognition of dysfunction sub-
types. This functional classification allows adequate treat-
ment for the different types and early proactive treatment
for the bladder at risk [6].
It is important for the practitioner to understand the
complexities involved in performing urodynamic studies in
newborns,infants,andchildren. Urodynamicassessmentcan
provide reproducible results in newborns and infants, but it
requires attention to mechanical factors and filling rates. The
younger the child, the higher the risk that mechanical factors
(such as bladder-outlet obstruction by the catheter used for
the investigation) may produce artificial information
(elevated leak pressure or inability to void). It has also been
shown that using a bladder infusion rate as close as possible
to the natural filling rate is important for correct assessment
of detrusor properties [24]. It is presumed that fast infusion
rates overcome vesicoelastic detrusor properties, falsely
indicating detrusor hypertonicity [11]. On the other hand, in
children who have apparent low-pressure cystograms and
who leak during filling (due to sphincter hypoactivity),
detrusor hypertonia may be unrecognized [25]. In these
children, it is important to perform a provocative study
(including bladder neck occlusion with a balloon catheter)
to identify unrecognized detrusor hyperactivity prior to
bladder-neck surgery for treatment of incontinence. Elec-
tromyographic (EMG) evaluation of the external urethral
sphincter is required to identify DSD. The use of concentric
EMG needles is preferred, as it gives more reliable
information than patch electrodes [11]. The combination
of X-ray cystography with cystometrogram and sphincter
EMG (video urodynamics) allows accurate evaluation of
the link between intravesical pressure and vesicoureteral
reflux and gives direct visual information of (dys)synergia
between detrusor and sphincter mechanisms [26].
Clean intermittent catheterisation
In children with neurogenic bladder, CIC is the first-choice
treatment to empty the bladder adequately (no residue, no
infection) and safely (prior to high-pressure voiding), and it
is a valuable tool for achieving continence. The wide
variety of used materials and techniques for CIC does not
seem to affect efficacy and safety as long as some basic
principles are applied: proper education and training, clean
and atraumatic application, and achievement of good
patient compliance on a long-term basis. For education,
training, and further guidance during follow-up, a dedicated
continence nurse is invaluable. Patients and caregivers must
understand what is wrong with the bladder/sphincter and
why CIC is proposed for treatment, and they have to learn
how to catheterize properly. CIC has been successfully used
by parents even in newborns and infants, becoming a part
of their everyday routine [27]. Some authors prefer early
institution of CIC in all infants with NBSD, given the fact
that by the age of 3 years, CIC will be required in all for
achieving continence, and given the difficulties of starting
CIC at toddler age [28]. Such early institution of CIC seems
to improve family compliance and their ability to assist the
child in coping with their disease and with CIC [29]. CISC
can be successfully taught to boys and girls who are
motivated and who have developed the required dexterity,
mostly around the age of 6 years. The required frequency of
catheterization depends on several factors: fluid intake,
bladder capacity, and bladder filling/voiding pressures. In
practice, it is recommended to catheterize six times a day in
infants (linked with feeding time) and five times a day in
school-aged children. Although reported incidences of CIC-
related infection risks are variable, it is generally agreed
that the risk is low as long as complete bladder emptying is
achieved. Furthermore, reused supplies are not related to
more urinary tract infections [30]. If symptomatic infections
occur, these are mainly caused by incomplete bladder
emptying, and CIC appliance by child or caregiver needs to
be optimized. To prevent urethral strictures and false
passage in boys, catheter lubrication and avoidance of
forceful manipulation during catheter insertion are advocat-
ed. Nonreusable low-friction catheters are considered
valuable in high-risk male patients with urethral false
passage or very tense sphincters but are unnecessary in
routine cases [31]. To maintain therapeutic compliance with
CISC in adolescents, psychosocial support is often re-
quired. Neurogenic bowel dysfunction with constipation
and fecal soiling can interfere with the institution of a
successful CIC treatment. Retained stools may mechanical-
ly impair bladder filling, increase detrusor irritability, or
contribute to urine retention. Stool incontinence increases
the risk of bladder contamination and urinary tract
infection. An effective bowel management program is
therefore needed. Finally, given the high prevalence of
latex allergy [32], in the spina bifida population, a strict
latex-free approach is of extreme importance.
Pharmacologic treatment: anticholinergics
Of the anticholinergic agents available, oxybutynin hydro-
chloride is most commonly used, and long-term experience
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Oxybutynin is a tertiary amine with a well-documented
therapeutic effect on detrusor hyperactivity, and its effec-
tiveness is attributed to a combination of anticholinergic
(M3-selective receptor subtype antagonism), antispasmod-
ic, local anesthetic and calcium-channel-blocking activity
[34]. Several studies have shown its efficacy for decreasing
the filling pressure, increasing the capacity of the neuro-
genic bladder, and preserving renal function [35–37]. The
usual dose regimen of oral oxybutynin is 0.3–0.6 mg/kg per
day in three doses.
In children with insufficient response or significant
systemic side effects to oral oxybutynin, intravesical instil-
lation of oxybutynin has been shown to be a highly
efficacious, reliable, and well-tolerated therapy for children
who would otherwise require surgical therapy [38–43].
Because a solution suitable for intravesical instillation was
not available, crushed oxybutynin tablets were used in the
earlier trials, with consequent problems of inconvenience
and impracticability, and it was the belief of several authors
that poor patient compliance could be resolved by an
optimized drug preparation [40, 44]. It was subsequently
shown that, indeed, eliminating the complex crushing
preparation by child or parent makes intravesical oxy-
butynin therapy easy to use and acceptable for long-term
therapy [41].
The mechanisms underlying the more potent and longer-
acting detrusor-suppressive effects of intravesical oxybu-
tyinin, as well as its better tolerability, have been
investigated by several groups. It was demonstrated that a
reduced first-pass metabolism of oxybutynin after intra-
vesical instillation, resulting in a reduced generation of the
N-desethyl metabolite, may explain the clinically relevant
reduction of systemic side effects that characterizes intra-
vesical compared with oral oxybutynin therapy [45]. In
addition, these pharmacokinetic studies provided first
evidence for a direct local rather than a systemic effect of
intravesical oxybutynin on detrusor muscle [45]. Further
evidence for a local effect of intravesically administered
oxybutynin was provided by studies showing local
(urothelial) accumulation, suppression of muscarinic recep-
tor-mediated detrusor muscle contractions, and blocking of
muscarinic receptors in bladder-afferent pathways [46, 47].
In most reports, intravesical oxybutynin is used in dosages
between 0.3 and 0.6 mg/kg per day in two or three doses.
Given its better tolerability compared with oral treatment, if
required, intravesical dosages can be further increased up to
doses of 0.9 mg/kg per day [43].
To date, the vast majority (∼ 90%) of patients can be
treated successfully with the gold standard treatment of
oxybutynin (oral or intravesical) and CIC. Other bladder-
relaxant drugs include propiverine (10–15 mg b.i.d. or t.i.d.,
adult dose), trospium (20 mg b.i.d., adult dose), extended-
releaseoxybutynin,andtolterodine(children0.25–1m gb. i .d .,
adults 1–2 mg b.i.d.). The current experience with compounds
other than oxybutynin is still limited in children with
neurogenic bladder [48, 49]. Botulinum A toxin injections
into the detrusor muscle have been shown to be a potentially
valuable approach in the neurogenic overactive bladder [50].
Repeated botulinum A toxin injections (as an alternative
for or an additive to anticholinergics) could be considered
to postpone or avoid surgical procedures in the small
minority of children not responding to standard therapy
with CIC and anticholinergics [51]. However, further
investigations are required, given remaining concerns about
costs and long-term efficacy and safety of prolonged
botulinum A toxin administration. Although some authors
have advocated alfa-receptor stimulation of the bladder
neck, no validated medical treatment is available to
enhance the bladder outlet.
Medical management of NBSD in clinical practice
Optimal management involves first, early diagnosis, in-
cluding recognition of high-risk subtypes, and second,
proactive institution of adequate treatment. Early proactive
treatment of high-pressure dyssynergic lower urinary tracts
is important in the long term, not only to preserve renal
function [52] but also to prevent poor bladder compliance
and the subsequent need for bladder augmentation [35].
Urodynamic assessment is used in newborns and infants to
come to a functional classification of NBSD, allowing
presymptomatic interventions in the high-risk groups and
individualized treatment planning according to the type of
dysfunction [6, 29, 53].
In clinical practice, four major subtypes can be used to
describe NBSD (Fig. 1): sphincter overactivity combined
with detrusor underactivity (type A) or overactivity (type
B), and sphincter underactivity combined with detrusor
underactivity (type C) or with detrusor overactivity (type
D). The easiest type to treat is type A. This bladder type
requires early treatment because of urine retention with
high filling pressure and continuous leaking. Here, CIC
alone is effective and sufficient and will make the bladder
safe and infection free, and the patient will be dry in
between (social continence). Good care to empty the
bladder totally is most important to avoid bladder infections
caused by residual urine. Dysfunctional type B will have
high filling and high voiding pressures, being very unsafe
from birth onward due to DSD. Here, the act of voiding has
to be prevented. With oxybutynin, the overactive detrusor
can be “pharmacologically converted” to an inactive
reservoir (situation similar to type A), which has to be
emptied with CIC. In type C, CIC reduces the degree of
incontinence and offers much better control over urinary
tract infections. To achieve continence, this type will at a
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sling operation). An important caveat here is that detrusor
instability may emerge only after surgical improvement of
outlet resistance. If this detrusor instability would remain
unrecognized and untreated (with oxybutynin), bladder-
outlet surgery would have converted a “wet but safe” into a
“dry but unsafe” bladder. In the last dysfunctional subtype
(type D), the bladder leaks due to detrusor instability and
gradually becomes unsafe due to secondary bladder-wall
changes with detrusor hypertrophy and loss of bladder
compliance. Therefore, treatment consists of CIC combined
with oxybutynin and, at a later age, bladder-outlet surgery.
Once appropriate therapy has been initiated, adequate
follow-up is required, with adjustments if needed (CIC
frequency, medication dosing and administration route).
Treatment efficacy can be assessed using clinical parame-
ters (including CIC frequency and volume charts), urinal-
ysis, renal and bladder ultrasound, X-ray cystography, and
video urodynamics.
As long-term sequelae of insufficiently treated neuro-
genic bladders (renal scarring, noncompliant fibrotic blad-
der) already have their origin in the first years of life, the
frequency of multidisciplinary follow-up visits must be age
dependent (3× yearly up to age 3 years, 2× yearly in
school-aged children, yearly in adults). Typically, urinalysis
and ultrasound are performed at all visits, cystography to
investigate unexpected upper urinary tract infections, and
urodynamics periodically to verify that under treatment, the
catheterized bladder volumes are age appropriate [54] and
stored under safe pressure conditions (storage of expected
bladder capacity at pressures below 30 cm H2O; see [55]).
With early instituted and optimal treatment, the large
majority of patients can be adequately controlled without
antireflux surgery or surgical bladder augmentation (Fig. 2).
Augmentation cystoplasty is limited to a small group of
patients in whom medical treatment fails (persistence of
high filling pressures). In patients with insufficient sphinc-
ter activity, continence achievement will require bladder-
outlet surgery in addition to medical treatment. In female
wheelchair users, surgical intervention to provide a conti-
nent stoma will facilitate self-catheterization.
Long-term outcome evaluation and need for life-long
follow-up
Lifelong follow-up with further periodic investigations of
upper urinary tract changes, renal function, and bladder
status is extremely important. There are two reasons why
long-term outcome evaluation in adulthood and life-long
patient follow-up are indispensable. First, for the individual
patient, therapy is a life-long requisite, and verifying
preservation of the patient’s kidneys is only possible by
repetitive assessment throughout adolescence and adult-
hood. Second, in general, detailed long-term follow-up data
will show whether a treatment policy driven by long-term
goals is sufficiently effective or requires further adaptations.
The effectiveness of efforts preserving upper urinary tract
function can only be judged by assessing the ultimate
outcome once these patients have reached adolescence or
adulthood [29]. In populations with NBSD, no consensus
exists as to how renal status is ideally evaluated [56]. In
clinical practice, upper urinary tract deterioration or
protection is often monitored by radiographic images of
hydronephrosis and vesicoureteral reflux. Modalities used
to look at renal functions include nuclear imaging [dimer-
captosuccinate acid (DMSA) renal scan], urinary concen-
trating ability, and glomerular filtration rate assessment. For
the latter, creatinine (Cr) clearance can be used for patients
who are socially continent; for others, inulin or Cr
ethylenediaminetetraacetate (EDTA) clearance can be used.
Which (combination) of these tests is best to evaluate renal
function requires further investigation [56].
Fig. 1 Classification of the neu-
rogenic bladder, with four sub-
types (a–d) according to
dysfunctional activities of
sphincter and detrusor. For each
subtype, clinical implications if
untreated and principles of
management are summarized
722 Pediatr Nephrol (2008) 23:717–725Conclusions
Medical management with CIC and anticholinergics is
effective in preserving renal function and providing safe
urinary continence in more than 90% of patients with a
neurogenic bladder. Early diagnosis and treatment institu-
tion, long before continence becomes an issue at toddler
age, can prevent both renal damage and secondary bladder-
wall changes, thereby improving long-term outcomes.
Compared with oral oxybutynin, intravesical oxybutynin
has more potent and longer-acting detrusor suppressive
effects with good tolerance and should be used prior to
considering surgical therapies. Therapeutic goals should no
longer be restricted to prevention of secondary damage to
both upper and lower urinary tracts. Instead, our goal
should be to achieve normal renal and bladder growth at
safe bladder pressure, with appliance-free continence.
Study questions
(Answers appear following the reference list)
Directions: Each of the numbered questions is followed by
several possible answers.
Select the one lettered answer that is NOT CORRECT in
each case.




c. Pattern of bladder dysfunction
2. Depending on the pattern of bladder dysfunction, safe
urinary continence can be achieved by:
a. CIC + anticholinergics + bladder-neck surgery
b. Bladder-neck surgery alone
c. CIC alone
3. Urodynamic risk factors for upper urinary tract deteri-
oration are:
a. DSD
b. High bladder compliance
c. Intravesical pressure >40 cm H2O
4. In a patient where CIC was started and in which
catheterized volumes are always far below the expected
bladder capacity for age:
a. There is no indication for CIC, and CIC can be
stopped
b. Anticholinergic treatment may need to be added to
CIC
c. Bladder-outlet resistance may be very insufficient
Fig. 2 Suppression of detrusor hyperactivity with resolution of reflux
by nonsurgical management. Illustrative patient with high-risk
neurogenic bladder sphincter dysfunction (NBSD) (type B), urody-
namically showing early unsafe filling pressures (A) with high-grade
reflux (a) and urosepsis before treatment. Under clean intermittent
catheterization (CIC) plus oxybutynin, the unsafe high-pressure
bladder was converted into a safe low-pressure reservoir with good
capacity and disappearance of the reflux at control cystography 3
months later (b). Severe systemic side effects, making continuation of
oral oxybutynin impossible, disappeared after switching to intravesical
oxybutynin. Further urodynamic evaluations (B: after first intravesical
administration; C: after 4 months) documented adequate suppression
of detrusor hyperactivity (modified from [40]). Long-term (currently
13 years) continuation of CIC and intravesical oxybutynin has resulted
in a safe and adequate capacity bladder with social continence for the
patient
Pediatr Nephrol (2008) 23:717–725 7235. In up to 90% of patients, optimal medical NBSD
management can prevent:
a. Vesicoureteral reflux surgery
b. Surgical augmentation cystoplasty
c. Bladder-outlet surgery
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